[Correspondence] Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance

Di |2024-08-22T00:30:01+02:00Agosto 22nd, 2024|Categorie: Coronavirus Lancet|

In their recent Article,1 Jean-Michel Molina and colleagues provide not only further evidence of the efficacy of doxycycline post-exposure prophylaxis (PEP) but also novel data showing that doxycycline PEP does not select for methicillin-resistant Stap...

[Comment] Re-evaluating polio vaccination strategies in Nepal: transitioning from OPV to fIPV for sustained immunity

Di |2024-08-22T00:30:01+02:00Agosto 22nd, 2024|Categorie: Coronavirus Lancet|

In 2014, WHO declared Nepal polio-free.1 However, recent detections of vaccine-derived poliovirus type-3 (VDPV3) in sewage samples from the Tukucha and Bagmati rivers have raised concerns.2 Similar detections were reported in Israel and Palestine betwe...

[Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Di |2024-08-21T00:30:01+02:00Agosto 21st, 2024|Categorie: Coronavirus Lancet|

This analysis is the first to provide estimates of the real-world effectiveness of the rVSV-ZEBOV vaccine against Ebola virus disease, amid the widespread use of the vaccine during a large Ebola virus disease outbreak. Our findings confirm that rVSV-ZE...

[Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Di |2024-08-21T00:30:01+02:00Agosto 21st, 2024|Categorie: Coronavirus Lancet|

This analysis is the first to provide estimates of the real-world effectiveness of the rVSV-ZEBOV vaccine against Ebola virus disease, amid the widespread use of the vaccine during a large Ebola virus disease outbreak. Our findings confirm that rVSV-ZE...

[Correspondence] The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus

Di |2024-08-21T00:30:01+02:00Agosto 21st, 2024|Categorie: Coronavirus Lancet|

WHO reported that as of the end of June, 2024, the multicountry mpox outbreak had caused a total of 99 176 laboratory-confirmed cases.1 The WHO has proposed developing mpox control and elimination plans from 2024 to 2025 in the Strategic Framework for ...

[Correspondence] The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus

Di |2024-08-21T00:30:01+02:00Agosto 21st, 2024|Categorie: Coronavirus Lancet|

WHO reported that as of the end of June, 2024, the multicountry mpox outbreak had caused a total of 99 176 laboratory-confirmed cases.1 The WHO has proposed developing mpox control and elimination plans from 2024 to 2025 in the Strategic Framework for ...

[Articles] Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Di |2024-08-15T00:30:01+02:00Agosto 15th, 2024|Categorie: Coronavirus Lancet|

PfSPZ Vaccine was safe and well tolerated in adults in Mali. The 9 × 105 and 1·8 × 106 doses of PfSPZ Vaccine administered as per the 4-week schedule, which incorporated presumptive antimalarial treatment before the first vaccine dose, showed significa...

[Articles] Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial

Di |2024-08-15T00:30:01+02:00Agosto 15th, 2024|Categorie: Coronavirus Lancet|

vYF has a similar safety and immunogenicity profile to YF-VAX. In general, the vYF 5 Log CCID50 dose appeared to show optimal viraemia, safety, and immunogenicity, and was chosen for subsequent development.

Torna in cima